Zura Bio Reports Third-Quarter 2026 Financial Results
Zura Bio reported financial results for the third quarter of 2026; the supplied text is truncated before any figures or further details.
Story updates
11:30:49 AM UTC
SquawkNews
TibuSHIELD topline data in hidradenitis suppurativa (HS) remains on track for Q4 2026; enrollment co
11:30:53 AM UTC
SquawkNews
Zura Bio reported Q3 2026 net loss of $25.8M ($0.20/share) and ended Q3 with $187.7M cash, which it expects will fund operations through at least end of 2028.Material DetailsContext by AI AnalystThis is an early-stage biotech update pairing cash runway with imminent and 2027 data catalysts. For a l…
Zura Bio Limited (NASDAQ:ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the third quarter end…